Who are stem cells infusion's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Casgevy, Platelet Rich Plasma (PRP), cART, Leukocyte rich platelet rich plasma, HPC, Cord Blood, ASC.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/stem-cells-infusion.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

stem cells infusion — Competitive Intelligence Brief

stem cells infusion (stem cells infusion) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Cell therapy. Area: Regenerative Medicine.

marketed Cell therapy Regenerative Medicine Small molecule Live · refreshed every 30 min

Target snapshot

stem cells infusion (stem cells infusion) — University of Campania Luigi Vanvitelli. Stem cell infusion delivers undifferentiated or progenitor cells that can differentiate, migrate to damaged tissues, and promote regeneration and immunomodulation.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
stem cells infusion TARGET	stem cells infusion	University of Campania Luigi Vanvitelli	marketed	Cell therapy
Casgevy	EXAGAMGLOGENE AUTOTEMCEL		marketed	Autologous genome-edited hematopoietic stem cell therapy	BCL11A	2023-01-01
Platelet Rich Plasma (PRP)	Platelet Rich Plasma (PRP)	Aspetar	marketed	Autologous cell therapy / Regenerative medicine
cART	cART	LI Taisheng	marketed	CAR-T cell therapy	Tumor-associated antigen (specific target depends on formulation)
Leukocyte rich platelet rich plasma	Leukocyte rich platelet rich plasma	University Hospitals Cleveland Medical Center	marketed	Autologous cell therapy / Regenerative medicine product
HPC, Cord Blood	HPC, Cord Blood	National Marrow Donor Program	marketed	Cell therapy; hematopoietic stem cell transplant
ASC	ASC	Anterogen Co., Ltd.	marketed	Autologous stem cell therapy

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Cell therapy class)

Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León · 2 drugs in this class
Bone Therapeutics S.A · 1 drug in this class
DiscGenics, Inc. · 1 drug in this class
Celavie Bioscences, LLC · 1 drug in this class
China Spinal Cord Injury Network · 1 drug in this class
City of Hope Medical Center · 1 drug in this class
Brainstorm-Cell Therapeutics · 1 drug in this class
Dr. Grant M. Pagdin · 1 drug in this class
FDA Office of Orphan Products Development · 1 drug in this class
Biosolution Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). stem cells infusion — Competitive Intelligence Brief. https://druglandscape.com/ci/stem-cells-infusion. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab